{"title":"不可切除肝细胞癌患者阿特唑单抗-贝伐单抗治疗后肌肉体积变化的影响","authors":"Hironori Ochi, Joji Tani, Tetsu Tomonari, Hironori Tanaka, Yusuke Imai, Takaaki Tanaka, Hideko Ohama, Fujimasa Tada, Atsushi Hiraoka, Akira Hirose, Chikara Ogawa, Asahiro Morishita, Akio Moriya, Yoshiko Nakamura, Masashi Hirooka, Akihiro Deguchi, SYMPLE Study Group","doi":"10.1111/hepr.14201","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>This study aimed to evaluate the prognostic impact of muscle volume changes during atezolizumab-bevacizumab (AB) combination therapy (AB therapy) for unresectable hepatocellular carcinoma (u-HCC). Additionally, we evaluated whether changes in muscle volume relate to prognosis based on treatment response.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The present retrospective, multicenter study included 165 patients with u-HCC treated with AB therapy at eight institutions.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The median albumin–bilirubin score in the entire cohort was −2.42. The objective response rate was 31.5%, and the disease control rate was 80.6%. The median overall survival (OS) was not reached, whereas the median progression-free survival (PFS) was 6.9 months (95% confidence interval [CI]: 5.3–8.5). At the first post-treatment computed tomography scan, patients were categorized into two groups: those with a nondecreased psoas muscle area index (PI) (group A) and those with a decreased PI (group B). The median OS was not reached in either group (<i>p</i> = 0.059). The median PFS was 10.5 months in group A and 5.5 months in group B (<i>p</i> = 0.025). Multivariate analysis using the Cox proportional hazards model identified alpha-fetoprotein ≥400 ng/mL (hazard ratio [HR]: 1.68; 95% CI: 1.11–2.54; <i>p</i> = 0.01) and decreased PI (HR: 1.59; 95% CI: 1.07–2.36; <i>p</i> = 0.02) as factors associated with PFS.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Nondecreased muscle volume after initiating AB therapy was associated with improved treatment efficacy and prognosis in patients with u-HCC.</p>\n </section>\n </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"55 7","pages":"1046-1053"},"PeriodicalIF":3.4000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of muscle volume changes following atezolizumab-bevacizumab therapy in patients with unresectable hepatocellular carcinoma\",\"authors\":\"Hironori Ochi, Joji Tani, Tetsu Tomonari, Hironori Tanaka, Yusuke Imai, Takaaki Tanaka, Hideko Ohama, Fujimasa Tada, Atsushi Hiraoka, Akira Hirose, Chikara Ogawa, Asahiro Morishita, Akio Moriya, Yoshiko Nakamura, Masashi Hirooka, Akihiro Deguchi, SYMPLE Study Group\",\"doi\":\"10.1111/hepr.14201\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>This study aimed to evaluate the prognostic impact of muscle volume changes during atezolizumab-bevacizumab (AB) combination therapy (AB therapy) for unresectable hepatocellular carcinoma (u-HCC). Additionally, we evaluated whether changes in muscle volume relate to prognosis based on treatment response.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>The present retrospective, multicenter study included 165 patients with u-HCC treated with AB therapy at eight institutions.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The median albumin–bilirubin score in the entire cohort was −2.42. The objective response rate was 31.5%, and the disease control rate was 80.6%. The median overall survival (OS) was not reached, whereas the median progression-free survival (PFS) was 6.9 months (95% confidence interval [CI]: 5.3–8.5). At the first post-treatment computed tomography scan, patients were categorized into two groups: those with a nondecreased psoas muscle area index (PI) (group A) and those with a decreased PI (group B). The median OS was not reached in either group (<i>p</i> = 0.059). The median PFS was 10.5 months in group A and 5.5 months in group B (<i>p</i> = 0.025). Multivariate analysis using the Cox proportional hazards model identified alpha-fetoprotein ≥400 ng/mL (hazard ratio [HR]: 1.68; 95% CI: 1.11–2.54; <i>p</i> = 0.01) and decreased PI (HR: 1.59; 95% CI: 1.07–2.36; <i>p</i> = 0.02) as factors associated with PFS.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Nondecreased muscle volume after initiating AB therapy was associated with improved treatment efficacy and prognosis in patients with u-HCC.</p>\\n </section>\\n </div>\",\"PeriodicalId\":12987,\"journal\":{\"name\":\"Hepatology Research\",\"volume\":\"55 7\",\"pages\":\"1046-1053\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatology Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/hepr.14201\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hepr.14201","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Impact of muscle volume changes following atezolizumab-bevacizumab therapy in patients with unresectable hepatocellular carcinoma
Aim
This study aimed to evaluate the prognostic impact of muscle volume changes during atezolizumab-bevacizumab (AB) combination therapy (AB therapy) for unresectable hepatocellular carcinoma (u-HCC). Additionally, we evaluated whether changes in muscle volume relate to prognosis based on treatment response.
Methods
The present retrospective, multicenter study included 165 patients with u-HCC treated with AB therapy at eight institutions.
Results
The median albumin–bilirubin score in the entire cohort was −2.42. The objective response rate was 31.5%, and the disease control rate was 80.6%. The median overall survival (OS) was not reached, whereas the median progression-free survival (PFS) was 6.9 months (95% confidence interval [CI]: 5.3–8.5). At the first post-treatment computed tomography scan, patients were categorized into two groups: those with a nondecreased psoas muscle area index (PI) (group A) and those with a decreased PI (group B). The median OS was not reached in either group (p = 0.059). The median PFS was 10.5 months in group A and 5.5 months in group B (p = 0.025). Multivariate analysis using the Cox proportional hazards model identified alpha-fetoprotein ≥400 ng/mL (hazard ratio [HR]: 1.68; 95% CI: 1.11–2.54; p = 0.01) and decreased PI (HR: 1.59; 95% CI: 1.07–2.36; p = 0.02) as factors associated with PFS.
Conclusions
Nondecreased muscle volume after initiating AB therapy was associated with improved treatment efficacy and prognosis in patients with u-HCC.
期刊介绍：
Hepatology Research (formerly International Hepatology Communications) is the official journal of the Japan Society of Hepatology, and publishes original articles, reviews and short comunications dealing with hepatology. Reviews or mini-reviews are especially welcomed from those areas within hepatology undergoing rapid changes. Short communications should contain concise definitive information.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
